147 related articles for article (PubMed ID: 24909179)
1. PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling.
Moody SE; Schinzel AC; Singh S; Izzo F; Strickland MR; Luo L; Thomas SR; Boehm JS; Kim SY; Wang ZC; Hahn WC
Oncogene; 2015 Apr; 34(16):2061-71. PubMed ID: 24909179
[TBL] [Abstract][Full Text] [Related]
2. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
Rexer BN; Chanthaphaychith S; Dahlman K; Arteaga CL
Breast Cancer Res; 2014 Jan; 16(1):R9. PubMed ID: 24451154
[TBL] [Abstract][Full Text] [Related]
3. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.
Wang YC; Morrison G; Gillihan R; Guo J; Ward RM; Fu X; Botero MF; Healy NA; Hilsenbeck SG; Phillips GL; Chamness GC; Rimawi MF; Osborne CK; Schiff R
Breast Cancer Res; 2011; 13(6):R121. PubMed ID: 22123186
[TBL] [Abstract][Full Text] [Related]
4. PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.
McDermott MS; Browne BC; Conlon NT; O'Brien NA; Slamon DJ; Henry M; Meleady P; Clynes M; Dowling P; Crown J; O'Donovan N
Mol Cancer; 2014 Jun; 13():157. PubMed ID: 24958351
[TBL] [Abstract][Full Text] [Related]
5. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.
Gajria D; Chandarlapaty S
Expert Rev Anticancer Ther; 2011 Feb; 11(2):263-75. PubMed ID: 21342044
[TBL] [Abstract][Full Text] [Related]
6. HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2
Xu X; De Angelis C; Burke KA; Nardone A; Hu H; Qin L; Veeraraghavan J; Sethunath V; Heiser LM; Wang N; Ng CKY; Chen ES; Renwick A; Wang T; Nanda S; Shea M; Mitchell T; Rajendran M; Waters I; Zabransky DJ; Scott KL; Gutierrez C; Nagi C; Geyer FC; Chamness GC; Park BH; Shaw CA; Hilsenbeck SG; Rimawi MF; Gray JW; Weigelt B; Reis-Filho JS; Osborne CK; Schiff R
Clin Cancer Res; 2017 Sep; 23(17):5123-5134. PubMed ID: 28487443
[No Abstract] [Full Text] [Related]
7. Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA.
Garay JP; Smith R; Devlin K; Hollern DP; Liby T; Liu M; Boddapati S; Watson SS; Esch A; Zheng T; Thompson W; Babcock D; Kwon S; Chin K; Heiser L; Gray JW; Korkola JE
Breast Cancer Res; 2021 Aug; 23(1):81. PubMed ID: 34344439
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast-tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways.
Zervantonakis IK; Poskus MD; Scott AL; Selfors LM; Lin JR; Dillon DA; Pathania S; Sorger PK; Mills GB; Brugge JS
Proc Natl Acad Sci U S A; 2020 Jul; 117(28):16500-16508. PubMed ID: 32601199
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer.
de Melo Gagliato D; Jardim DL; Marchesi MS; Hortobagyi GN
Oncotarget; 2016 Sep; 7(39):64431-64446. PubMed ID: 26824988
[TBL] [Abstract][Full Text] [Related]
10. MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.
Venturutti L; Cordo Russo RI; Rivas MA; Mercogliano MF; Izzo F; Oakley RH; Pereyra MG; De Martino M; Proietti CJ; Yankilevich P; Roa JC; Guzmán P; Cortese E; Allemand DH; Huang TH; Charreau EH; Cidlowski JA; Schillaci R; Elizalde PV
Oncogene; 2016 Dec; 35(48):6189-6202. PubMed ID: 27157613
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells.
Fonseca-Alves CE; Leis-Filho AF; Lacerda ZA; de Faria Lainetti P; Amorim RL; Rogatto SR
PLoS One; 2024; 19(4):e0297043. PubMed ID: 38564578
[TBL] [Abstract][Full Text] [Related]
12. Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer.
Sonnenblick A; Brohée S; Fumagalli D; Vincent D; Venet D; Ignatiadis M; Salgado R; Van den Eynden G; Rothé F; Desmedt C; Neven P; Loibl S; Denkert C; Joensuu H; Loi S; Sirtaine N; Kellokumpu-Lehtinen PL; Piccart M; Sotiriou C
BMC Med; 2015 Aug; 13():177. PubMed ID: 26234940
[TBL] [Abstract][Full Text] [Related]
13. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition.
Rexer BN; Ham AJ; Rinehart C; Hill S; Granja-Ingram Nde M; González-Angulo AM; Mills GB; Dave B; Chang JC; Liebler DC; Arteaga CL
Oncogene; 2011 Oct; 30(40):4163-74. PubMed ID: 21499296
[TBL] [Abstract][Full Text] [Related]
14. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications.
Garrett JT; Arteaga CL
Cancer Biol Ther; 2011 May; 11(9):793-800. PubMed ID: 21307659
[TBL] [Abstract][Full Text] [Related]
15. Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer.
Eroglu Z; Tagawa T; Somlo G
Oncologist; 2014 Feb; 19(2):135-50. PubMed ID: 24436312
[TBL] [Abstract][Full Text] [Related]
16. HDAC Inhibition Restores Response to HER2-Targeted Therapy in Breast Cancer via
Clayton NS; Carter EP; Fearon AE; Heward JA; Rodríguez Fernández L; Boughetane L; Wilkes EH; Cutillas PR; Grose RP
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047202
[TBL] [Abstract][Full Text] [Related]
17. The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer.
Zanini E; Louis LS; Antony J; Karali E; Okon IS; McKie AB; Vaughan S; El-Bahrawy M; Stebbing J; Recchi C; Gabra H
Mol Cancer Ther; 2017 Oct; 16(10):2246-2256. PubMed ID: 28775148
[TBL] [Abstract][Full Text] [Related]
18. Current approaches and future directions in the treatment of HER2-positive breast cancer.
Hurvitz SA; Hu Y; O'Brien N; Finn RS
Cancer Treat Rev; 2013 May; 39(3):219-29. PubMed ID: 22658319
[TBL] [Abstract][Full Text] [Related]
19. HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway.
Smith AE; Ferraro E; Safonov A; Morales CB; Lahuerta EJA; Li Q; Kulick A; Ross D; Solit DB; de Stanchina E; Reis-Filho J; Rosen N; Arribas J; Razavi P; Chandarlapaty S
Nat Commun; 2021 Nov; 12(1):6667. PubMed ID: 34795269
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2-extracellular domain in human cancer cells.
Yoshida R; Tazawa H; Hashimoto Y; Yano S; Onishi T; Sasaki T; Shirakawa Y; Kishimoto H; Uno F; Nishizaki M; Kagawa S; Fujiwara T
Cancer Immunol Immunother; 2012 Nov; 61(11):1905-16. PubMed ID: 22465967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]